证券代码：300204 证券简称：舒泰神 公告编号：2025-055 舒泰神（北京）生物制药股份有限公司 第六届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"）第六 届监事会第九次会议（以下简称"本次会议"）的通知以电话、电子邮件等相结合 的方式于 2025 年 09 月 05 日送达，本次会议于 2025 年 09 月 08 日下午 15:30 在 北京经济技术开发区经海二路 36 号公司会议室以现场结合通讯表决方式召开。 本次会议应出席监事 3 名，实际出席监事 3 名，现场表决监事 2 名，通讯表决监 事 1 名。本次会议由监事张洪山先生召集和主持，与会监事表决。 一、审议通过《关于公司符合向特定对象发行股票条件的议案》 根据《中华人民共和国公司法》、《中华人民共和国证券法》和《上市公司 证券发行注册管理办法》等法律、法规和规范性文件的有关规定，公司董事会结 合公司实际情况，对照上市公司向特定对象发行股票相关资格、条件进行了逐项 自查，监事会认为公司已符合向特定对 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-054 舒泰神（北京）生物制药股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 第六届董事会第九次会议（以下简称"本次会议"）通知以电话、电子邮件等相结 合的方式于 2025 年 09 月 05 日发出，本次会议于 2025 年 09 月 08 日下午 15:00 在北京经济技术开发区经海二路 36 号公司会议室，以现场结合通讯方式召开。 本次会议应出席董事 7 名，实际出席董事 7 名，现场表决的董事 5 名，通讯表 决的董事 2 名。公司监事、高级管理人员列席了会议。本次会议的召集与召开符 合《中华人民共和国公司法》（以下简称"《公司法》"）和《舒泰神（北京）生物 制药股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 本次会议由董事长周志文先生召集和主持，与会董事经过充分讨论和认真审 议，一致同意并通过了如下决议： 一、审议通过《关于公司符合向特定对象发行股票条件的议案》 根 ...

每经AI快讯，9月9日，舒泰神（300204）(300204.SZ)公告称，拟定增募资不超过12.53亿元，用于创新 药物研发项目、补充流动资金。 ...

2025年9月8日，舒泰神（北京）生物制药股份有限公司发布公告，鉴于拟向特定对象发行股票，公司对 近五年是否被证券监管部门和交易所采取监管措施或处罚进行自查。结果显示，公司近五年不存在被处 罚情况。监管措施方面，2020年因特定关联交易违反首发承诺，深交所下发问询函，中国证监会北京监 管局对公司及董事长采取监管谈话措施。公司高度重视并整改，与关联方协商收益返还等事宜，相关人 员接受监管谈话，还组织学习证券法规，加强关联交易管理。除上述情形，无其他监管措施情况。 ...

（编辑 楚丽君） 证券日报网讯 9月5日晚间，舒泰神发布公告称，持股5%以上股东香塘集团有限公司将其所持有的部分 股份解除质押，本次解除质押股数为250万股，占其所持股份比例6.81%，占公司总股本比例0.52%，质 权人为中国农业银行股份有限公司太仓分行。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-052 | 苏州香塘同 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 轩科技有限 | | 4.5067 | 0.01% | 0 | 0% | 0% | 0 | 0% | 0 | 0% | | 公司 | | | | | | | | | | | | 合 | 计 | 3,674.0075 | 7.69% | 3,005.0000 | 81.89% | 6.29% | - | - | - | - | 三、备查文件 舒泰神（北京）生物制药股份有限公司 关于股东部分股份解除质押的公告 持股 5%以上股东香塘集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏 舒泰神（北京）生物制药股份有限公司（以下简称"本公司"或"舒泰神"） 近日接到持股 5%以上股东香塘集团有限公司（以下简称"香塘集团 ...

Core Viewpoint - The innovative drug concept stocks experienced a decline, with several companies seeing significant drops in their stock prices [1] Group 1: Stock Performance - Shuyou Shen and Qianyan Biology both fell over 10% [1] - Fuyuan Pharmaceutical hit the daily limit down [1] - Baihua Pharmaceutical, Asia-Pacific Pharmaceutical, Wanbangde, Bailitianheng, and Ruizhiyiyuan all dropped over 5% [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.89% on September 2, with Shuyatian leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Ziji Shenzhou (688235) with a closing price of 324.85, up 8.28% [1] - Mengke Pharmaceutical (688373) at 8.26, up 8.12% [1] - Haichen Pharmaceutical (300584) at 68.49, up 7.22% [1] - Other significant performers included: - Beilu Pharmaceutical (300016) at 10.78, up 6.94% [1] - Warner Pharmaceutical (688799) at 56.73, up 5.56% [1] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.388 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.034 billion yuan [4] - Key stocks with notable capital flows included: - Baijishenzhou (688235) with a net inflow of 1.56 billion yuan from institutional investors [4] - Beilu Pharmaceutical (300016) with a net outflow of 41.53 million yuan from retail investors [4] ETF Information - The Huaxia Sci-Tech 100 ETF (product code: 588800) tracks the Shanghai Stock Exchange Sci-Tech 100 Index and has seen a 4.38% change over the last five days [6] - The current PE ratio stands at 231.01, with a recent reduction in shares by 65 million, indicating a net outflow of 782,000 yuan from institutional investors [6]

Group 1 - The core viewpoint of the article highlights significant changes in fund holdings across various sectors, with notable increases in the pharmaceutical, banking, and electronics sectors, while the power equipment, food and beverage, and coal sectors experienced declines [1] - As of the end of the reporting period, the largest three sectors by fund holding scale are electronics, pharmaceuticals, and power equipment [1] - Individual stocks that saw the highest increase in fund holding as a percentage of circulating market value include Shutai Shen, Anglikang, and Weichai Heavy Industry [1] Group 2 - In terms of fund holding market value growth, Guotai Haitong, Shenghong Technology, and Zijin Mining lead the rankings [1] - The concentration of fund holdings is highest in Nocera Health, Maolai Optics, and Dekeli, while the top three in terms of fund holding market value are Ningde Times, Kweichow Moutai, and China Merchants Bank [1]

Core Viewpoint - The stock of Shuyou Shen has experienced significant fluctuations, with a year-to-date increase of 587.45%, but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of August 29, Shuyou Shen's stock price was 50.94 CNY per share, with a market capitalization of 24.338 billion CNY [1]. - The stock has seen a trading volume of 3.21 billion CNY, with a turnover rate of 1.36% [1]. - Year-to-date, the stock has risen by 587.45%, but has decreased by 2.99% in the last five trading days and 2.17% in the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14% [2]. - The net profit attributable to shareholders was -24.636 million CNY, representing a year-on-year decrease of 619.70% [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700 [2]. - The average number of circulating shares per shareholder decreased by 22.60% to 14,327 shares [2]. - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, several new institutional shareholders have emerged among the top ten circulating shareholders, including: - Xingquan Helun Mixed A (163406) as the third-largest shareholder with 15.721 million shares [3]. - Xingquan Commercial Model Mixed (LOF) A (163415) as the fifth-largest shareholder with 8.805 million shares [3]. - Other new shareholders include Xingquan New Vision and Yongying Medical Innovation [3].